The role of estrogen receptors and their polymorphism in endothelial dysfunction and atherosclerosis;Rola receptorów estrogenowych i ich polimorfizmu w wystepowaniu zaburzeń funkcji śródbłonka i rozwoju miażdżycy

Advances in Clinical and Experimental Medicine

Volumn 14, Issue 6, 2005, Pages 1289-1293

  Zdsrojiewicz, Zygmunt ^a   Dubiński, Andrzej ^b   Dubińska, Katarzyna ^b  

^a Katedra i Klinika Endokrynologii   (Poland)

^b Powiatowe Centrum Zdrowia   (Poland)

Author keywords

Atherosclerosis; Estrogen receptors; Polymorphism

Indexed keywords

ESTROGEN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; PLATELET DERIVED GROWTH FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR MECHANICS; PATHOGENESIS; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT;

EID: 31444432474     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Bello N, Mosca B: Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 2004, 46, 287-295.
2. Brass LM: Hormone replacement therapy and stroke: clinical trials review. Stroke. 2004, 35, Suppl. 1, 2644-2647.
3. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, Blumenthal R, Barett-Connor E, Hulley S, Heart and Estrogen/progestin Replacement Study Research Group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Inter Med 2003, 138, 81-89.
4. Hulley S, Furberg C, Barret-Conno, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D, HERS Research Group: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002, 288, 58-66.
5. Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigaton: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349, 523-534.
6. Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized trial. JAMA 2004, 291, 1701-1712.
7. Borgfelt C, Li C, Samsioe G: Low-dose oral combination of 17 beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 2004, 7, 78-85.
8. Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA, Yeh J, Lee ET: Associations of post-menopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and non-diabetic american Indian women: the strong heart study. J Womens Health (Larchmt) 2004, 13, 155-163.
9. Miller AP, Feng W, Xing D, Wethington NM, Blalock JE, Chen YF, Oparil S: Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004, 110, 1664-1669.
10. Seed M, Knopp RH: Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. Curr Opin Lipidol 2004, 15, 459-467.
11. Zhu W, Everson WV, Smart EJ: Estrogen in cardiovascular disease. Curr Opin Lipidol 2004, 15, 589-593.
12. Karas RH, Patterson B, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994, 89, 1943-1950.
13. Phiel KL, Henderson RA, Adelman SJ, Elloso MM: Differential estrogen receptor gen expression in human peripheral blood mononuclear cell populations. Immunol Lett 20, 97, 107-113.
14. Barchiesi F, Jackson EK, Imthurn J, Fingerle J, Gillespie DG, Dubey RK: Differential regulation of estrogen receptor subtypes alpha and beta in human aortic smooth muscle cells by oligonucleotides and esteradiol. J Clin Endocrinol Metab 2004, 89, 373-2381.
15. Muller-Delp JM, Lubahn DB, Nichol KE, Philips BJ, Price EM, Curran EM, Laughlin MH: Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-alfa-deficient mice. Am J Physiol Heart Circ Physiol 2003, 285, 2150-2157.
16. Liang M, Ekblad E, Lydrup ML, Nilsson BO: Combined lack of estrogen receptrors alpha and beta affects vascular iNOS protein expression. Cell Tissue Res 2003, 313, 63-70.
17. Widder J, Pelzer T, von Poser-Klein C, Hu K, Jazbutyte V, Fritzemeier KH, Hegele-Hartung C, Neyses L, Bauersachs J: Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 2003, 42, 991-996.
18. Nakamura Y, Igarashi K, Suzuki T, Kanno J, Inoue T, Tazawa C, Saruta M, Ando T, Moriyama N, Furukawa T, Ono M, Moriya T, Ito K, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H: EAF1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis. Am J Pathol 2004, 165, 2019-2031.
19. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H: Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Moll Cell Endocrinol 2004, 219, 17-26.
20. Losordo DW, Kearney M, Kim EA: Variable expression of he estrogen receptor in normal and atherosclerotic coronary arteries of postmenopausal women. Circulation 1994, 89, 1501-1510.
21. Kortelainen ML, Huttunen P: Expression of estrogen receptors in the coronary arteries of young and postmenopausal women in relation to central obesity. Int J Obes Relat Metab Disord 2004, 28, 623-627.
22. Geraldes P, Sirois MG, Tanguay JF: Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003, 93, 399-405.
23. Mori M, Tsukahara F, Yoshioka T, Irie K, Ohta H: Suppression by 17 beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci 2004, 75, 599-609.
24. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG: Estrogen recepor alfa gene polymorphisms and risk of myocardial infarction. JAMA 2004, 291, 2969-2977.
25. Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi E, Wijns W: Estrogen receptor-polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol 2003, 23, 2223-2234.
26. Almeida S, Franken N, Zandona MR, Osorio-Wender MC, Hutz MH: Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J 2004, 5, 30-34.
27. Lu H, Higashikata T, Inazu A, Nohara A, Yu W, Shimizu M, Mabuchi H: Association of estrogen receptor-alfa gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. 2002, 22, 817-823.
28. Malacara JM, Perez-Luque EL, Martinez-Garza S, Sanchez-Marin FJ: The relationship of estrogen receptor-alfa polymorphism with symptoms and other characteristcs in post-menopausal women. Maturitas 2004, 49, 163-169.
29. Pertyński T, Stachowiak G: Bezpieczna hormonalna terapia zastepcza. Scheringówka. 2004, 2, 21-23,